Mesenchymal Stem Cell Exosomes in the Treatment of Myocardial Infarction: a Systematic Review of Preclinical In Vivo Studies,Journal of Cardiovascular Translational Research

当前位置： X-MOL 学术 › J. of Cardiovasc. Trans. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Mesenchymal Stem Cell Exosomes in the Treatment of Myocardial Infarction: a Systematic Review of Preclinical In Vivo Studies
Journal of Cardiovascular Translational Research ( IF 2.4 ) Pub Date : 2021-10-05 , DOI: 10.1007/s12265-021-10168-y
Hui Meng ₁ , Weiting Cheng ₁ , Lei Wang ₁ , Shiqi Chen ₁ , Yu Teng ₁ , Ziwen Lu ₁ , Yang Li ₁ , Mingjing Zhao ₁

Affiliation

Several prior studies have highlighted the promise of mesenchymal stem cells (MSCs) as tools for treating myocardial infarction (MI) patients. While MSCs were initially thought to mediate post-MI repair through differentiation and replacement of injured cells, they are now thought to function by releasing exosomes carrying important cargos which can prevent apoptosis and facilitate revascularization in the context of MI. Herein, we comprehensively survey prior preclinical studies examining MSC-derived exosomes (MSC-Exos) utility for the repair of MI-related tissue injury. In total, 24 relevant studies were identified in the PubMed, Web of Science, Embase, and Cochrane Library databases as per the PRISMA guidelines. In most studies, exosome-treated rodents exhibited improved cardiac function and angiogenesis together with decreased apoptotic cell death. MSC-Exos thus offer beneficial therapeutic efficacy when treating MI injury. However, further work will be necessary to standardize experimental preclinical models and to validate these results.

Graphical abstract

This systematic review provides a comprehensive overview of previous preclinical studies on the utility of exosomes derived from mesenchymal stem cells (MSCs) in the repair of myocardial infarction (MI) injury.

中文翻译：

间充质干细胞外泌体治疗心肌梗死：临床前体内研究的系统评价

先前的几项研究强调了间充质干细胞 (MSCs) 作为治疗心肌梗塞 (MI) 患者的工具的前景。虽然最初认为 MSC 通过分化和替换受损细胞来介导 MI 后修复，但现在认为它们通过释放携带重要货物的外泌体发挥作用，这些货物可以防止细胞凋亡并促进 MI 情况下的血运重建。在此，我们全面调查了先前的临床前研究，这些研究检查了 MSC 衍生的外泌体 (MSC-Exos) 用于修复 MI 相关组织损伤的效用。根据 PRISMA 指南，总共在 PubMed、Web of Science、Embase 和 Cochrane 图书馆数据库中确定了 24 项相关研究。在大多数研究中，外泌体处理的啮齿动物表现出改善的心脏功能和血管生成以及减少的凋亡细胞死亡。因此，MSC-Exos 在治疗 MI 损伤时提供了有益的治疗效果。然而，需要进一步的工作来标准化实验临床前模型并验证这些结果。